John F. Lyons

5.9k total citations · 2 hit papers
81 papers, 4.3k citations indexed

About

John F. Lyons is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John F. Lyons has authored 81 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 21 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John F. Lyons's work include Cancer-related Molecular Pathways (12 papers), Microtubule and mitosis dynamics (10 papers) and Acute Myeloid Leukemia Research (10 papers). John F. Lyons is often cited by papers focused on Cancer-related Molecular Pathways (12 papers), Microtubule and mitosis dynamics (10 papers) and Acute Myeloid Leukemia Research (10 papers). John F. Lyons collaborates with scholars based in United States, Germany and United Kingdom. John F. Lyons's co-authors include Kurt Grünewald, Hans G. Feichtinger, Gideon Bollag, Henry R. Bourne, Orlo H. Clark, Frank McCormick, Barbara Hibner, S M Wilhelm, Lucia Vallar and Griffith Harsh and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

John F. Lyons

78 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two G Protein Oncogenes in Human Endocrine Tumors

1990 827 citations John F. Lyons, Hans G. Feichtinger et al. profile →
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

2003 631 citations Guillermo Garcia‐Manero, John F. Lyons et al. profile →

Peers

Countries citing papers authored by John F. Lyons

Since Specialization

Citations

This map shows the geographic impact of John F. Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Lyons more than expected).

Fields of papers citing papers by John F. Lyons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Lyons. The network helps show where John F. Lyons may publish in the future.

Co-authorship network of co-authors of John F. Lyons

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Lyons. A scholar is included among the top collaborators of John F. Lyons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Lyons. John F. Lyons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma 2024 ·Cancer Research Communications ·George A. Ward, Zhiqiang Zhang, Simone Jueliger, (unknown), Matthew P. Davis, (unknown), (unknown), Harold Keer, (unknown), John F. Lyons, Martin Sims, Tomoko Smyth	2
2	ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth 2018 ·Molecular Cancer Therapeutics ·George A. Ward, Edward J. Lewis, Jong Sook Ahn, Christopher N. Johnson, John F. Lyons, (unknown), Joanne M. Munck, Sharna J. Rich, Tomoko Smyth, Neil T. Thompson, Pamela A. Williams, Nicola E. Wilsher, Nicola G. Wallis, Gianni Chessari	53
3	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations 2018 ·Clinical Cancer Research ·(unknown), Fang Fang, Ali Özeş, Jessica Tang, (unknown), Harold Keer, John F. Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz V. Rassool, Kathy D. Miller, Kenneth P. Nephew	95
4	First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John F. Lyons, Daruka Mahadevan	75
5	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study 2014 ·Clinical Cancer Research ·Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, (unknown), Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, (unknown), Murray Yule, Darren Hargrave	39
6	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer 2014 ·Clinical Cancer Research ·Fang Fang, Joanne M. Munck, Jessica Tang, Pietro Taverna, Yinu Wang, David F. Miller, Jay Pilrose, Gavin Choy, Mohammad Azab, Katherine S. Pawelczak, Pamela S. VanderVere-Carozza, Michael Wagner, John F. Lyons, Daniela Matei, John J. Turchi, Kenneth P. Nephew	81
7	A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis 2013 ·Clinical Lymphoma Myeloma & Leukemia ·James M. Foran, Farhad Ravandi, William G. Wierda, Guillermo Garcia‐Manero, Srđan Verstovšek, Tapan M. Kadia, Jan A. Burger, Murray Yule, Gillian Langford, John F. Lyons, John Ayrton, Victoria Lock, G. Borthakur, Jörge E. Cortes, Hagop M. Kantarjian	37
8	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models 2012 ·Molecular Cancer Therapeutics ·Tomoko Smyth, Thomas Van Looy, Jayne Curry, Ana M. Rodrı́guez-López, Agnieszka Woźniak, Mei‐Jun Zhu, (unknown), (unknown), Mark Mayeda, Jonathan A. Fletcher, Patrick Schöffski, John F. Lyons, Neil T. Thompson, Nicola G. Wallis	49
9	A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies 2011 ·Annals of Oncology ·Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife, David Olmos, Timothy A. Yap, Matthew Squires, Sara Lewis, Victoria Lock, Murray Yule, John F. Lyons, Hilary Calvert, Ian Judson	52
10	The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer 2011 ·Cancer Science ·Brent Graham, Jayne Curry, Tomoko Smyth, Lynsey Fazal, Ruth E. Feltell, (unknown), (unknown), Brian Williams, Matthias Reule, Hayley C. Angove, David M. Cross, John F. Lyons, Nicola G. Wallis, Neil T. Thompson	65
11	AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders 2010 ·British Journal of Haematology ·Mark A. Dawson, Jayne Curry, (unknown), Philip Beer, Brent Graham, John F. Lyons, Caroline J. Richardson, Mike Scott, Tomoko Smyth, Matthew Squires, Neil T. Thompson, Anthony R. Green, Nicola G. Wallis	41
12	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines 2009 ·Molecular Cancer Therapeutics ·Matthew Squires, Ruth E. Feltell, Nicola G. Wallis, Edward J. Lewis, Donna-Michelle Smith, David M. Cross, John F. Lyons, Neil T. Thompson	134
13	AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation. 2007 ·Molecular Cancer Therapeutics ·John F. Lyons, (unknown), Steven J. Woodhead, Ruth E. Feltell, Matthias Reule, (unknown), Lisa C. A. Seavers, (unknown), (unknown), Donna Smith, Lynsey Fazal, Paul Workman, Ian Collins, Michelle D. Garrett, Neil T. Thompson	2
14	Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines. 2007 ·Cancer Research ·Neil T. Thompson, John F. Lyons, (unknown), Rachel McMenamin, Sheetal Patel, (unknown), Jon Lewis, Lynsey Fazal, Andrew Woodhead, Brent Graham, Christopher W. Murray	2
15	Characterisation of aurora kinase inhibitors derived from fragment based lead discovery 2006 ·Cancer Research ·Neil J. Gallagher, John F. Lyons, Jayne Curry, Matthias Reule, Valério Berdini, Dominic Tisi, Lynsey Fazal, Steven Howard, Paul G. Wyatt, Adrian L. Gill	2
16	Internationalizing The Teaching Of Early U.S. History 2005 ·Teaching History A Journal of Methods ·John F. Lyons	1
17	The polymerase chain reaction and cancer diagnostics 1992 ·Cancer ·John F. Lyons	9
18	Molecular genetic analysis of DNA obtained from fixed, air dried or paraffin embedded sources 1991 ·Annals of Hematology ·K Grünewald, John F. Lyons, (unknown), J. W. G. Janssen, Hans G. Feichtinger, CR Bartram	22
19	Incidence of ras gene mutations in neuroblastoma 1988 ·European Journal of Pediatrics ·(unknown), John F. Lyons, (unknown), Claus R. Bartram	27
20	A re-evaluation of the South African species of Lemboides Stebbing and Lembos Bate (Amphipoda, Aoridae) described by K.H. Barnard (1916) 1987 ·Deep Sea Research Part B Oceanographic Literature Review ·(unknown), John F. Lyons, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact